StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell

StockNews.com downgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a sell rating in a research note released on Monday morning.

Other equities analysts have also issued reports about the company. D. Boral Capital restated a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Tuesday, January 7th. HC Wainwright started coverage on shares of Immunic in a research report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Trading Down 0.1 %

Immunic stock opened at $0.96 on Monday. The firm has a market capitalization of $86.49 million, a PE ratio of -0.78 and a beta of 1.87. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11. The firm’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.28.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in Immunic in the third quarter worth approximately $50,000. HB Wealth Management LLC purchased a new stake in shares of Immunic in the 4th quarter valued at $81,000. Jane Street Group LLC grew its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the period. Finally, State Street Corp lifted its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.